Trexquant Investment LP Acquires 11,174 Shares of Progyny, Inc. (NASDAQ:PGNY)

Trexquant Investment LP lifted its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 1.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 600,163 shares of the company's stock after buying an additional 11,174 shares during the period. Trexquant Investment LP owned about 0.70% of Progyny worth $10,353,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Signaturefd LLC raised its holdings in Progyny by 1,355.0% during the 4th quarter. Signaturefd LLC now owns 1,455 shares of the company's stock worth $25,000 after buying an additional 1,355 shares during the period. GAMMA Investing LLC lifted its position in Progyny by 341.4% in the 4th quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in Progyny by 108.4% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock worth $51,000 after purchasing an additional 1,526 shares during the period. Caitlin John LLC increased its holdings in Progyny by 2,974.8% during the 4th quarter. Caitlin John LLC now owns 3,290 shares of the company's stock worth $57,000 after purchasing an additional 3,183 shares in the last quarter. Finally, SBI Securities Co. Ltd. acquired a new stake in shares of Progyny in the 4th quarter valued at about $74,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 price objective for the company in a report on Monday, March 31st. Bank of America boosted their price objective on shares of Progyny from $21.00 to $25.00 and gave the stock a "buy" rating in a research report on Tuesday, February 11th. Canaccord Genuity Group lifted their price target on shares of Progyny from $17.00 to $23.00 and gave the company a "hold" rating in a research note on Friday, February 28th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Progyny from $17.00 to $23.00 and gave the stock a "neutral" rating in a research note on Tuesday, January 28th. Eight investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat, Progyny has an average rating of "Hold" and a consensus target price of $23.64.

Remove Ads

Progyny Stock Performance

Shares of NASDAQ PGNY traded down $0.93 during mid-day trading on Monday, reaching $21.67. The company had a trading volume of 488,668 shares, compared to its average volume of 1,709,499. Progyny, Inc. has a one year low of $13.39 and a one year high of $36.36. The business's 50-day simple moving average is $22.19 and its 200 day simple moving average is $18.45. The firm has a market cap of $1.85 billion, a price-to-earnings ratio of 37.11, a PEG ratio of 2.39 and a beta of 1.33.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.